Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
IEC 61689:2013 — Ultrasonics — Physiotherapy Systems
IEC 61689:2013 is the globally recognized benchmark for therapeutic ultrasound equipment used in physiotherapy. It defines the performance, safety, and measurement requirements that directly impact treatment efficacy and patient safety.
Introduction
IEC 61689:2013, titled “Ultrasonics — Physiotherapy systems — Field specifications and methods of measurement in the frequency range 0.5 MHz to 5 MHz,” establishes standardized methods for specifying and measuring the output characteristics of ultrasonic physiotherapy equipment. Therapeutic ultrasound is one of the most widely used modalities in physical therapy, applied for deep tissue heating, pain relief, inflammation reduction, and accelerated tissue healing.
The standard was significantly revised from its 2002 edition to address advances in transducer technology and to resolve ambiguities in measurement methodology. The 2013 edition includes improved definitions for effective radiating area (ERA), beam non-uniformity ratio (BNR), and introduces requirements for array-based therapy applicators. These parameters are critical determinants of treatment dosage and clinical outcomes.
Ultrasound physiotherapy equipment with high BNR (> 6:1) can produce localized hot spots in tissue that may cause patient discomfort or even tissue damage. Always verify BNR values before clinical use.
Scope and Key Parameters
The standard applies to ultrasonic physiotherapy systems operating in the frequency range of 0.5 MHz to 5 MHz, with output intensities up to 3 W/cm² (spatial-average temporal-average intensity, ISATA). The key output parameters defined and measured under this standard include:
| Parameter | Symbol | Definition | Typical Requirement |
|---|---|---|---|
| Effective Radiating Area | ERA | The area of the transducer face that actively radiates ultrasound | ≥ 80% of geometric area |
| Beam Non-uniformity Ratio | BNR | Ratio of peak to average intensity over the ERA | ≤ 6:1 (ideally ≤ 4:1) |
| Spatial-Average Temporal-Average Intensity | ISATA | Total power divided by ERA, time-averaged | 0.1 to 3.0 W/cm² |
| Total Output Power | P | Total acoustic power emitted from the transducer | Typically 3 to 20 W |
| Operating Frequency | f | Nominal center frequency of the transducer | 1 MHz or 3 MHz (common) |
| Pulse Repetition Frequency | PRF | Rate of pulse bursts in pulsed mode | 100 Hz (typical) |
| Effective Intensity | IE | Time-averaged intensity during the burst period | 0.5 to 2.0 W/cm² |
ERA and BNR together determine the effective treatment area and the uniformity of energy deposition. A 5 cm² transducer with ERA = 4 cm² and BNR = 4:1 delivers substantially more uniform heating than one with ERA = 3 cm² and BNR = 8:1, even at the same ISATA setting.
Measurement Methods and Instrumentation
Radiation Force Balance
The primary method for measuring total output power is the radiation force balance technique. An absorbing or reflecting target intercepts the ultrasound beam, and the measured radiation force is proportional to the total acoustic power. The standard specifies target design (types: absorbing cone, reflecting cone, or absorbing disc), tank dimensions, degassed water requirements (dissolved oxygen ≤ 2 mg/L), and positioning accuracy.
Hydrophone Scanning
For ERA and BNR determination, the standard requires scanning a calibrated hydrophone across the transducer field in a plane parallel to the transducer face, typically at a distance of 5-10 mm from the applicator. The scanned area must extend beyond the -20 dB contour of the beam. The hydrophone must have a receiving element diameter no greater than 0.5 mm for accurate spatial resolution at 3 MHz and above.
Acoustic Output Characterization
The standard defines specific test conditions: degassed, deionized water at 22 °C ± 3 °C, with the transducer mounted in a free-field configuration (no reflecting boundaries within 10 cm of the transducer face). Measurements must be performed after a 30-minute warm-up period to ensure thermal stability of the transducer.
Degassed water is not optional. Dissolved gas in untreated tap water nucleates cavitation at diagnostic and therapeutic intensity levels, causing acoustic streaming artifacts that can corrupt ERA and BNR measurements by 20-40%. Always verify dissolved oxygen levels before testing.
Engineering Insights for Quality Assurance
1. Transducer Aging and Performance Drift. Piezoelectric ceramic elements used in physiotherapy transducers undergo gradual depolarization over their operational life, particularly when driven at high power levels. IEC 61689 recommends annual output verification. Studies show that transducers with more than 500 treatment hours can exhibit ERA reduction of 10-20% and BNR increases of 20-40%, potentially compromising treatment uniformity. Clinical engineering departments should maintain a transducer life log.
2. Coupling and Air Bubble Management. Air bubbles trapped between the transducer face and the patient’s skin are a major cause of treatment inconsistency. The standard emphasizes that ERA measurements must be performed with proper coupling. In clinical practice, bubble-induced reflections can reduce delivered intensity by 30-50% at the treatment site. Degassed ultrasound gel and slow transducer movement are recommended practices.
3. Frequency Selection for Treatment Depth. The 2013 standard clarifies the relationship between frequency and treatment depth. At 1 MHz, 50% of the incident intensity penetrates to approximately 3-5 cm depth; at 3 MHz, the same 50% penetration occurs at only 1-2 cm. Clinicians should select frequency based on target tissue depth, and biomedical engineers should verify that the indicated frequency corresponds to the actual measured output frequency within ± 5%.
4. Quality Assurance Protocol Integration. Implementing IEC 61689-based QA in a clinical setting requires a dedicated test station comprising a radiation force balance, a needle hydrophone with scanning system, and a degassing apparatus. The capital investment (typically $15,000-$30,000) is justified by the ability to detect performance degradation before it affects patient outcomes. Many manufacturers offer QA kits that comply with the standard’s measurement requirements.
Frequently Asked Questions
1. What is the clinical significance of the Beam Non-uniformity Ratio (BNR)?
BNR indicates how evenly the ultrasound energy is distributed across the treatment area. A BNR of 4:1 means the peak intensity is four times the average intensity. High BNR values (> 6:1) can create localized hot spots that cause periosteal pain or tissue damage. The International Society for Medical Ultrasound recommends BNR ≤ 5:1 for safe clinical practice.
2. How does pulsed versus continuous mode affect treatment?
Continuous mode delivers uninterrupted ultrasound energy, producing primarily thermal effects (tissue heating). Pulsed mode (typically 20% duty cycle, 100 Hz PRF) delivers the same peak intensity but with lower average power, producing predominantly non-thermal effects (cavitation, acoustic streaming, micro-massage). The selection between modes depends on the treatment goal: thermal for chronic conditions requiring tissue heating, pulsed for acute inflammation requiring mechanical stimulation.
3. Why must the water used for testing be degassed?
Dissolved gas in water forms microbubbles when exposed to the rarefaction phase of the ultrasound wave. These bubbles scatter and attenuate the ultrasound beam, causing underestimation of output power and distortion of beam profile measurements. The standard specifies dissolved oxygen levels ≤ 2 mg/L, which requires either vacuum degassing or boiling and cooling the water before use.
4. Can IEC 61689 be applied to multi-element array transducers?
Yes. The 2013 edition introduced specific requirements for array-based therapy applicators. Each individual element must meet the ERA and BNR criteria, and the combined field must also be characterized. The standard requires additional measurements of inter-element crosstalk and phase alignment for phased-array systems used in advanced physiotherapy applications.
